^
    2ms
    Study of HMPL-760 Puls R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Hutchmed
    New P2 trial
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • HMPL-760
    almost2years
    HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL (clinicaltrials.gov)
    P1, N=0, Withdrawn, Hutchmed | N=168 --> 0 | Trial completion date: Oct 2025 --> Nov 2022 | Recruiting --> Withdrawn | Trial primary completion date: Apr 2025 --> Nov 2022
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    CCL2 (Chemokine (C-C motif) ligand 2)
    |
    HMPL-760
    over2years
    HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL (clinicaltrials.gov)
    P1, N=168, Recruiting, Hutchison Medipharma Limited | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CCL2 (Chemokine (C-C motif) ligand 2)
    |
    HMPL-760
    almost3years
    HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL (clinicaltrials.gov)
    P1, N=168, Not yet recruiting, Hutchison Medipharma Limited
    New P1 trial
    |
    CCL2 (Chemokine (C-C motif) ligand 2)
    |
    HMPL-760